Review
Version 1
Preserved in Portico This version is not peer-reviewed
Mechanistic and Translational Advances Using iPSC-Derived Blood Cells
Version 1
: Received: 26 September 2020 / Approved: 27 September 2020 / Online: 27 September 2020 (08:39:30 CEST)
How to cite: Thom, C. S.; Chou, S. T.; French, D. L. Mechanistic and Translational Advances Using iPSC-Derived Blood Cells. Preprints 2020, 2020090672. https://doi.org/10.20944/preprints202009.0672.v1 Thom, C. S.; Chou, S. T.; French, D. L. Mechanistic and Translational Advances Using iPSC-Derived Blood Cells. Preprints 2020, 2020090672. https://doi.org/10.20944/preprints202009.0672.v1
Abstract
Human induced pluripotent stem cell (iPSC)-based model systems can be used to produce blood cells for the study of both hematologic and non-hematologic disorders. This commentary discusses recent advances that have utilized iPSC-derived red blood cells, megakaryocytes, myeloid cells, and lymphoid cells to model hematopoietic disorders. In addition, we review recent studies that have defined how microglial cells differentiated from iPSC-derived monocytes impact neurodegenerative disease. Related translational insights highlight the utility of iPSC models for studying pathologic anemia, bleeding, thrombosis, autoimmunity, immunodeficiency, blood cancers, and neurodegenerative disease such as Alzheimer’s.
Keywords
iPSC; hematopoiesis; developmental biology; anemia; thrombosis; immunodeficiency; cancer
Subject
Biology and Life Sciences, Anatomy and Physiology
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment